H S Mueller
Overview
Explore the profile of H S Mueller including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
528
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Srinivas V, Cannon C, Gibson C, Antman E, Greenberg M, Tanasijevic M, et al.
Am Heart J
. 2001 Jun;
142(1):29-36.
PMID: 11431653
Objective: We sought to identify, by use of serum cardiac markers, patients at low risk for 30-day mortality after ST-segment elevation myocardial infarction. Background: Baseline cardiac markers are currently used...
2.
Kizer J, Cannon C, McCabe C, Mueller H, Schweiger M, Davis V, et al.
Am Heart J
. 1999 Jan;
137(1):79-92.
PMID: 9878939
Background: Although studies have documented that randomized, controlled trials (RCTs) have a measurable influence on clinical practice, investigators have uncovered important deficiencies in the application of RCT findings to the...
3.
Cannon C, Gibson C, McCabe C, Adgey A, Schweiger M, Sequeira R, et al.
Circulation
. 1998 Dec;
98(25):2805-14.
PMID: 9860780
Background: Bolus thrombolytic therapy is a simplified means of administering thrombolysis that facilitates rapid time to treatment. TNK-tissue plasminogen activator (TNK-tPA) is a highly fibrin-specific single-bolus thrombolytic agent. Methods And...
4.
Mueller H, Chatterjee K, Davis K, Fifer M, Franklin C, Greenberg M, et al.
J Am Coll Cardiol
. 1998 Sep;
32(3):840-64.
PMID: 9741535
No abstract available.
5.
Cannon C, McCabe C, Borzak S, Henry T, Tischler M, Mueller H, et al.
Circulation
. 1998 Feb;
97(4):340-9.
PMID: 9468207
Background: Inhibitors of the platelet glycoprotein IIb/IIIa receptor given intravenously have been shown to be effective in reducing ischemic complications after coronary angioplasty and in unstable angina, making this a...
6.
Mueller H, Forman S, Menegus M, Cohen L, Knatterud G, Braunwald E
J Am Coll Cardiol
. 1995 Oct;
26(4):900-7.
PMID: 7560615
Objectives: This study sought to assess the independent contribution of nonfatal reinfarction to the risk of subsequent death in patients with acute myocardial infarction undergoing thrombolytic therapy. Background: A composite...
7.
Cannon C, Thompson B, McCabe C, Mueller H, Kirshenbaum J, Herson S, et al.
Am J Cardiol
. 1995 May;
75(15):977-81.
PMID: 7747698
Among patients with acute ischemic syndromes, patients with non-Q-wave acute myocardial infarction (AMI) are known to be at higher risk for death, reinfarction, and other morbidity than those with unstable...
8.
Cannon C, McCabe C, Henry T, Schweiger M, Gibson R, Mueller H, et al.
J Am Coll Cardiol
. 1994 Apr;
23(5):993-1003.
PMID: 8144799
Objectives: The purpose of this study was to assess the value of recombinant desulfatohirudin (hirudin) as adjunctive therapy to thrombolysis in acute myocardial infarction. Background: Failure to achieve initial reperfusion...
9.
Mueller H
Cardiology
. 1994 Jan;
84(3):168-74.
PMID: 8205566
IACP has played an important role in the evolution of the therapy of cardiogenic shock. Although IACP has not developed to an independent treatment modality, it is an essential adjunct...
10.
Terrin M, WILLIAMS D, Kleiman N, Willerson J, Mueller H, Desvigne-Nickens P, et al.
J Am Coll Cardiol
. 1993 Dec;
22(7):1763-72.
PMID: 8245326
Objectives: This report describes the survival and reinfarction rates for 2- and 3-year follow-up in the Thrombolysis in Myocardial Infarction (TIMI) Phase II clinical trial. Background: Patients enrolled in TIMI...